Drugs drugs everywhere, can you access ones that work? Kirstin Spencer

Here at METUPUK, we know drug access is a big issue for all metastatic breast cancer patients. There have been huge leaps and bounds made in terms of research, knowledge

METUPUK at the UK Interdisciplinary Breast Cancer Symposium

METUPUK (Metastatic Exchange To Unleash Power) attended the 2024 United Kingdom’s Interdisciplinary Breast Cancer Symposium in Birmingham, hosted by Breast Cancer Now and supported by numerous partners. It was a

Dr Rachel Eyre interviews Dr Hannah Harrison about breast cancer research

Scientific research is vital for the development of new and improved treatments for secondary breast cancer. But what’s it like to be a scientist working in this area? Dr Hannah Harrison received her PhD in breast cancer research from the University of Manchester in 2009 and has since worked as a breast cancer research scientist in the Manchester Cancer Research Centre. Here, Hannah tells us about her work.

How smarter therapies can help metastatic breast cancer patients – and why we need more!

Why we need MBC research more than ever

At METUPUK, we campaign for new and better therapies for patients with secondary breast cancer. One of our recent campaigns, #TrodelvyNow helped to make a new type of drug, Trodelvy (sacituzumab govitecan) available for SBC patients in the UK. Scientist and METUPUK volunteer, Helen, explains how Trodelvy works and why it’s important that more drugs like this get to patients urgently.

Postcode Lotteries

What’s your postcode and what does that say about you? If I asked a healthy person about the importance of their postcode I suspect they’d tell me about local schools,

Email complaint to CRUK May 2020

We attach an email complaint from METUP UK to CRUK (we have received a response this week – see below after the complaint) We are a patient-led advocacy group, lobbying

ABC5 Lisbon – The Global Alliance

Key Messages This was my first time at this conference which is held in Lisbon every 2 years and focuses entirely on Advanced Breast Cancer.  Jo had been to the

A good thing? F*** off!

Soon after my diagnosis with secondary breast cancer aged 33 someone tried to explain to me that my diagnosis could be viewed as a good thing. I don’t know why